Cargando…
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Autores principales: | Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636322/ https://www.ncbi.nlm.nih.gov/pubmed/35736670 http://dx.doi.org/10.1182/bloodadvances.2022007812 |
Ejemplares similares
-
S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023) -
P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023) -
Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022) -
Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021) -
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)